New hope pill tested for tough blood cancers
NCT ID NCT06846606
Summary
This early-stage study is testing a new oral medication called AUTX-703 for adults with advanced forms of blood cancer (AML or MDS) that have returned or stopped responding to other treatments. The main goal is to find a safe dose and see how the body handles the drug. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University, The James Comprehensive Cancer
Columbus, Ohio, 43210, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Sarah Cannon Center for Blood Cancer at TriStar Centennia
Nashville, Tennessee, 37203, United States
-
UPENN Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.